immunotherapy Archives -

NICE backs Aimmune’s peanut allergy drug Palforzia for children

Phil Taylor Aimmune, DBV Technologies, HEOR, immunotherapy, NHS, NICE, Palforzia, peanut allergy, Viaskin Peanut 0 Comment

Children in England with peanut allergies could be among the first in Europe to get access to Aimmune’s

NICE backs Aimmune’s peanut allergy drug Palforzia for children

https://pharmaphorum.com/news/nice-backs-aimmunes-peanut-allergy-drug-palforzia-for-children/

Oncology/ Views & Analysis/ Views and analysis

Using bispecific antibodies to advance cancer immunotherapy

mike.hammerton@pharmaphorum.com cancer, immunotherapy 0 Comment

Dr Laura Moriarty, senior marketing manager at Bio-Rad, looks at the impressive immuno-therapeutic potential of bispecific antibodies (bsAbs).

Using bispecific antibodies to advance cancer immunotherapy

https://pharmaphorum.com/oncology/bispecific-antibodies-cancer-immunotherapy/

Digital/ News/ News

Allergy specialist Stallergenes taps Aptar for digital delivery

Phil Taylor allergy, Aptar, digital, digital health, immunotherapy, non-adherence, Stallergenes Greer 0 Comment

Stallergenes Greer has teamed up with Aptar Pharma to develop a digital dimension for its allergen immunotherapy (AIT)

Allergy specialist Stallergenes taps Aptar for digital delivery

https://pharmaphorum.com/news/allergy-specialist-stallergenes-taps-aptar-for-digital-delivery/

R&D/ Views & Analysis/ Views and analysis

Targeting COVID-19 and cancer with immunotherapy advancements

mike.hammerton@pharmaphorum.com : Anna Biosciences, cancer, COVID-19, immuno-oncology, immunotherapy, Oncology 0 Comment

Anna Biosciences’ Dr Anthony Rullo discusses the drug development company’s immunotherapy platform. Over the last 30 years, we

Targeting COVID-19 and cancer with immunotherapy advancements

https://pharmaphorum.com/r-d/targeting-covid-19-cancer-immunotherapy-advancements/

Oncology/ Slider in video/ Video/ Views & Analysis/ Views and analysis

Health Innovators – Jo Brewer, Adaptimmune

Paul Tunnah Adaptimmune, cell therapy, health innovators, immunotherapy, Innovation 0 Comment

In this episode of Health Innovators, pharmaphorum founder Paul Tunnah interviews Jo Brewer, senior vice president of allogeneic

Health Innovators – Jo Brewer, Adaptimmune

https://pharmaphorum.com/video/health-innovators-jo-brewer-adaptimmune/

Deep Dive/ Digital/ Market Access/ Oncology/ R&D/ Views & Analysis/ Views & Analysis/ Views & Analysis/ Views and analysis

Deep Dive: Oncology 2021

George Underwood asco, ASCO 2021, COVID-19, Deep Dive, digital health, immuno-oncology, immunotherapy, Oncology 0 Comment

This has probably been the toughest year for oncology researchers in memory. As this issue’s contributors discuss, funding

Deep Dive: Oncology 2021

https://pharmaphorum.com/views-analysis-oncology/deep-dive-oncology-2021/

NICE’s track record in cancer drugs: the impact of the CDF and the role of interim funding

Oncology/ Views & Analysis/ Views and analysis

Changing focus to cachexia may be key to improved cancer outcomes

Catherine Longworth cachexia, cancer, immunotherapy, Oncology 0 Comment

Cachexia could be the next blockbuster area in cancer therapeutics because of its link to survival outcomes. Physician

Changing focus to cachexia may be key to improved cancer outcomes

https://pharmaphorum.com/views-analysis-oncology/changing-focus-to-cachexia-may-be-key-to-improved-cancer-outcomes/

Can in vivo imaging deliver the full potential of immunotherapy

Oncology/ R&D/ Views & Analysis/ Views & Analysis/ Views and analysis

The next generation of immunotherapy? Innate Pharma targets NK cells

Catherine Longworth immunotherapy, Innate Pharma, Oncology, Sezary Syndrome 0 Comment

Clinical-stage oncology biotech Innate Pharma is on a mission to harness the power of natural killer cells to

The next generation of immunotherapy? Innate Pharma targets NK cells

https://pharmaphorum.com/views-and-analysis/the-next-generation-of-immunotherapy-innate-pharma/

Digital/ Events/ Events

Triple Negative Breast Cancer Drug Development Digital Summit

jenna.warren@hansonwade.com adc, immunotherapy, Oncology, PARP inhibitor, TNBC 0 Comment

Fast-track the Discovery & Development of TNBC

Triple Negative Breast Cancer Drug Development Digital Summit

https://pharmaphorum.com/events/triple-negative-breast-cancer-drug-development-digital-summit/

Trending

immunotherapy

Login